Kinnate Biopharma Inc. 10-K Cybersecurity GRC - 2024-03-28

Page last updated on April 11, 2024

Kinnate Biopharma Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-28 16:12:43 EDT.

Filings

10-K filed on 2024-03-28

Kinnate Biopharma Inc. filed an 10-K at 2024-03-28 16:12:43 EDT
Accession Number: 0001140361-24-016132

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity. Risk Management and Strategy We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. We conduct risk assessments to identify cybersecurity threats at least annually, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks. Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks, reasonably address any identified gaps in existing safeguards and regularly monitor the effectiveness of our safeguards. We devote internal and external resources and designate high-level personnel, including our Chief Operating Officer, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process. 78 Table of Contents As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, in collaboration with human resources, IT and management. Personnel at all levels and departments are made aware of our cybersecurity policies through trainings. We engage third parties in connection with our risk assessment processes. These service providers assist us in designing and implementing our cybersecurity policies and procedures, as well as monitoring and testing our safeguards. We believe that our business strategy, results of operations and financial condition have not been materially affected as a result of any previously identified cybersecurity incidents at this time but we cannot provide assurance that they will not be materially affected in the future by any such incidents or any future material incidents. For additional information regarding risks related to cybersecurity threats, please refer to Item 1A, Risk Factors, in this Annual Report on Form 10-K, including the risk factor entitled Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer actual or suspected security or data privacy breaches or incidents or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations, and potentially significant delays in our delivery to market . Governance One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the nominating and corporate governance committee. Our Chief Operating Officer, in conjunction with our information security team and third-party consultants, are primarily responsible for assessing and managing our material risks from cybersecurity threats. Our Chief Operating Officer oversees our cybersecurity policies and processes, including those described in Risk Management and Strategy above. The processes by which our Chief Operating Officer is informed about and monitors the prevention, detection, mitigation and remediation of cybersecurity incidents includes vulnerability reports, security awareness training results and security tool threat detections. Our Chief Operating Officer provides briefings to the nominating and corporate governance committee of the board of directors regarding our company s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties and the like. In addition, our Chief Operating Officer provides the nominating and corporate governance committee annual updates of cybersecurity risks and activities and the board of directors briefings of any significant cybersecurity matters.


Company Information

NameKinnate Biopharma Inc.
CIK0001797768
SIC DescriptionPharmaceutical Preparations
TickerKNTE - Nasdaq
Website
Category
Emerging growth company
Fiscal Year EndDecember 30